Silexion Therapeutics LTD (SLXN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SLXN
- Company Silexion Therapeutics LTD
- Price $0.95
- Changes Percentage -7.77
- Change -0.08
- Day Low $0.91
- Day High $0.99
- Year High $13.56
- Year Low $0.21
- Market Cap $8,953,162
- Price Avg 50 EMA (D) $1.06
- Price Avg 200 EMA (D) $2.72
- Exchange NASDAQ
- Volume 66,590,261
- Average Volume 14,707,749
- Open $0.99
- Previous Close $1.03
- EPS -39.75
- PE -0.03
- Earnings Announcement 2025-05-28 12:00:00
- Shares Outstanding $8,692,390
Company brief: SILEXION THERAPEUTICS LTD (SLXN )
- Healthcare
- Biotechnology
- Mr. Ilan Hadar M.B.A.
- https://silexion.com
- IL
- N/A
- 04-07-2021
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.